drugset / Trial / NCT00828646

Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese

NCT00828646

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics, and pharmacodynamics following 14-day multiple oral doses BMS-708163 in healthy young male Japanese and healthy elderly male and female Japanese subjects

Timeline

Start
2008-10
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Avagacestat Small molecule 50 mg Oral
Subject Avagacestat Small molecule 75 mg Oral
Subject Avagacestat Small molecule 100 mg Oral

Indications

No indication recorded.